2 M.D. Kilis State Hospital, Eye Clinic, Kilis/TURKEY
3M.D. Asistant Professor, 100. Yil University Faculty of Medicine, Department of Ophthalmology, Van/TURKEY
4M.D. Professor, 100. Yil University Faculty of Medicine, Department of Ophthalmology, Van/TURKEY Purpose: To evaluate the steroid-induced glaucoma and its treatment with medication or surgery.
Material and Methods: Twenty-three eyes of 14 patients with steroid-induced glaucoma were retrospectively evaluated in the Ophthalmology Department of Yuzuncu Yil University between 1996 and 2009. All patients have increased IOP, glaucomatous optic disc damage and glaucomatous visual field loss.
Results: The patient?s mean age was 32.09±15.58. Topical steroid use was the most frequent cause for glaucoma (71.4%). Topical dexamethasone 0.1% was predominantly used by 13 eyes. The most common cause for steroid use was vernal keratoconjunctivitis (5 patients). The baseline and post-treatment IOP were 39±13.5 mmHg and 12.9±3.4 mmHg, respectively. The vertical cup-disc ratio was 0.69±2.2. In 9 patients (73.5%), IOP could be controlled by topical medications alone, whereas 5 patients (26.5%) required surgery.
Conclusion: Steroid-induced glaucoma can occur with topical or systemic steroid administration. In the present study, IOP could have been controlled in all patients with medical or surgical therapy. Patients receiving potent topical or systemic steroids have a potential risk for increased IOP and glaucoma. Patients must be informed of this risk by their ophthalmologists. The careful monitoring is essential for patients with glaucoma risk.
Keywords : Antiglaucomatous treatment, glaucoma, steroid